Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration
Authors
Keywords
-
Journal
BJU INTERNATIONAL
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-04-29
DOI
10.1111/bju.15434
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neoadjuvant Gemcitabine-Cisplatin plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-Invasive Bladder Cancer: a 12-year experience
- (2020) G. Iyer et al. Clinical Genitourinary Cancer
- Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses.
- (2020) Stephane Culine et al. JOURNAL OF CLINICAL ONCOLOGY
- European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
- (2020) J. Alfred Witjes et al. EUROPEAN UROLOGY
- IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
- (2020) Maha H. A. Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.
- (2019) Thomas W. Flaig et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies
- (2019) Andrea Necchi et al. EUROPEAN UROLOGY
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- (2019) Thomas Powles et al. NATURE MEDICINE
- Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy
- (2018) Homayoun Zargar et al. JOURNAL OF UROLOGY
- Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
- (2018) Dipen J Parekh et al. LANCET
- Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy
- (2018) N. Vasdev et al. WORLD JOURNAL OF UROLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer
- (2018) Charles C. Peyton et al. JAMA Oncology
- Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial
- (2018) Jürgen E. Gschwend et al. EUROPEAN UROLOGY
- Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?
- (2016) Homayoun Zargar et al. JOURNAL OF UROLOGY
- Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis
- (2016) Ming Yin et al. ONCOLOGIST
- Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
- (2015) Matthew D. Galsky et al. CANCER
- Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
- (2015) Homayoun Zargar et al. EUROPEAN UROLOGY
- Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
- (2015) Elizabeth R. Plimack et al. EUROPEAN UROLOGY
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
- (2014) Woonyoung Choi et al. CANCER CELL
- Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates
- (2014) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
- (2014) E. M. Van Allen et al. Cancer Discovery
- Correlation of Pathologic Complete Response with Survival After Neoadjuvant Chemotherapy in Bladder Cancer Treated with Cystectomy: A Meta-analysis
- (2013) Fausto Petrelli et al. EUROPEAN UROLOGY
- Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California
- (2012) Adrian S. Fairey et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
- (2011) JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started